

IMPACT OF NATURAL OILS SUPPLEMENTS ON DISEASE ACTIVITY AND ANTIOXIDANT STATE OF EGYPTIAN PATIENTS WITH RHEUMATOID ARTHRITIS

SAHAR Y. AL-OKBI*

NAGWA M. AMMAR**

KH.A. SOROOR***

DOHA A. MOHAMMED*

SUMMARY: The present research was established to study the effect of oral supplementation of different natural oils on the anti-oxidant state, plasma trace elements, prostaglandin E₂, activities of transaminases, uric acid and creatinine and erythrocyte sedimentation rate (ESR) in Egyptian patients with rheumatoid arthritis (RA). The natural oils used in this study were fish oil, evening primrose and Nigella sativa, in conjunction with vitamin E and were supplemented for two months to RA patients. Additional group of patients was given synthetic anti-inflammatory drugs.

Results showed that supplementation of any of the above referred natural oils, significant reduction of the activities of erythrocyte superoxide dismutase (SOD), ESR, plasma copper, prostaglandin E₂, and creatinine with significant increase of plasma zinc were noticed in RA patients. Administration of either fish oil or primrose oil produced significant increase of plasma vitamin C and decrease of plasma uric acid. The serum of RA patients that were given primrose showed significant increase of plasma vitamin E. Fish oil was the only supplement that produced reduction in plasma activities of transaminases. It was noticed that administration of synthetic anti-inflammatory drugs produced significant increase of plasma vitamin C and significant decrease of plasma copper and prostaglandin E₂.

The present research included studying the antioxidant state and the different biochemical parameters when the previously mentioned natural oils were administered simultaneously during consumption of either low or high caloric diet in RA patients.

Concerning the antioxidant state, especially the elevating effect of plasma vitamin C and the reducing effect of the activities of erythrocyte SOD, the best natural oil in this respect was fish oil followed by primrose then Nigella, the synthetic drug had the best least effect. Primrose was superior in elevating plasma vitamin E.

Plasma prostaglandin E₂ was efficiently reduced by fish oil supplementation followed by synthetic drugs then primrose oil which was more efficient than Nigella oil.

Key Words: Rheumatoid arthritis, antioxidant state, natural oils, disease activity.

INTRODUCTION

Rheumatoid arthritis is a chronic inflammatory disease characterized by joint swelling, synovial inflam-

mation and cartilage destruction (1). Essential fatty acids have a unique role as precursor molecules of chemical regulators of inflammatory cell function (2). These regulators are the prostaglandins and the leukotrienes, compounds synthesized and released by almost every tissue in the body and participating in many biological functions, including the inflammatory and immune processes (3).

*From Department of Food Sciences and Nutrition,

**From Department of Pharmacology, National Research Centre, Dokki, Cairo, Egypt.

***From Department of Rheumatology and Rehabilitation, Medical Military Academy, Cairo, Egypt.

Altering the essential fatty acids content of the diet or administering different essential fatty acids as supplements may modify the production of the various prostaglandins and leukotrienes. Supplementation of fish oil rich in eicosapentaenoic acid (20:5 ω -3) and docosahexaenoic acid (22:6 ω -3) might have successful results in the treatment of rheumatoid arthritis. The mechanisms which might account for these anti-inflammatory effects, including conversion of these polyunsaturated fatty acids to biologically less active eicosanoids (prostaglandin E₃, thromboxane B₃ and leukotriene B₅) (4, 5).

The ingestion of a diet rich in evening primrose (*Oenothera biennis* L. family Oenotheraceae) oil rich in δ -linolenic acid (18:3 ω -6) elevates serum dihommo- δ -linolenic acid (20:3 ω -6) concentrations, resulting in an increase in the 1-series prostaglandins, prostaglandin E₁ (6). Prostaglandin E₁ has a negative feedback role in chronic inflammation, initially aiding the development of the cardinal signs of inflammation but later suppressing inflammation. So evening primrose oil might be useful in a disease characterized by inflammation such as rheumatoid arthritis.

The whole powdered seeds of *Nigella sativa* L. Family Ranunculaceae as well as the successive petroleum and alcoholic extracts revealed a remarkable anti-inflammatory activity in experimental rats (7). Fixed oil of *Nigella sativa* and derived thymoquinone has been shown to inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation (8). Only scanty studies of the anti-inflammatory action of *Nigella sativa* were conducted on human and even the majority of these studies were done on asthma (9), no previous studies have been in rheumatoid arthritis, the present study might be the first in this concern.

The main goal of the present work was to study to what extent oral administration of natural oils (fish oil, evening primrose oil and *Nigella sativa* oil) together with vitamin E might have therapeutic activity towards rheumatoid arthritis patients in comparison to synthetic drugs. To fulfill this aim a follow up study of certain biochemical parameters, including antioxidants, trace elements and parameters reflecting disease activity, before and after the natural oils' administration was carried out in rheumatoid arthritis patients.

MATERIALS AND METHODS

Materials

Three natural oils in form of capsules were used in our study.

1. Animal origin

Fish oil (Salmon oil): Commercial name: EPA, obtained from Minapharm-Egypt from Pharmagel-Switzerland.

2. Botanical Origin

Evening primrose seeds oil (Oenothera Biennis L. family Oenotheraceae): Commercial name: Primaleve, obtained from Glaxo Wellcome Egypt,

Nigella sativa oil (Nigella sativa L. family Ranunculaceae): Commercial name: Nigellar, obtained from Kahira Pharmaceuticals and Chemical Industries Company Cairo-Egypt,

In addition, Vitamin E, obtained from Pharco Pharmaceuticals, Alexandria-Egypt were used.

Subjects

The study included 112 rheumatoid arthritis male patients as outpatients aged 30-70 years attending the Rheumatology Clinic, Kobry El-Koba Military Hospital.

Methods

Determination of fatty acids and unsaponifiable fractions of the different natural oils:

Three grams of each of the three natural fixed oils (fish oil, evening primrose oil and *Nigella sativa* oil) under investigation, were saponified by refluxing with 10% alcoholic potassium hydroxide. After dilution with distilled water, the unsaponifiable fraction was extracted with ether. Both aqueous (saponifiable) and non-aqueous portions (unsaponifiable) were separated in separating funnel. The ether was evaporated, and the extract was weighed and kept for further investigation of unsaponifiable matter. The aqueous mother liquor, in each case, was acidified with 10% hydrochloric acid and the liberated fatty acids were extracted with ether. Ether was evaporated and the residue was weighed and kept for studying the total fatty acids (10, 11). The unsaponifiable fraction of the three natural oils under investigation was analyzed by Gas Liquid Chromatography (GLC). Identification of hydrocarbons and sterols contents of the unsaponifiable fraction was carried out by comparison of their retention times and co-injection with the available authentic reference compounds [(cholesterol, campesterol, β -sitosterol, β -amyryne (E. Merck, Darmstadt, Germany)]. Quantitation was based on peak area integration. GLC conditions were stationary phase: Chromosorb W-HP, detector temperature 290°C, injector temperature 28°C, carrier gas N₂, flow-rate 30 ml/min, air flow-rate 300 ml/min, H₂ flow-rate 30 ml/min, detector FID, chart speed 0.5 cm/min, oven program: Initial temperature 70°C, final temperature 270°C, programmed 4°C/min. For 50 min maintained for 35 min at 270°C, total

Table 1: GLC analysis of unsaponifiable matter of the different natural fixed oils (as percentage of total hydrocarbon).

Hydrocarbons	Fish oil	Primrose oil	<i>Nigella sativa</i> oil
Dodecane C12	-	0.528	-
Tetradecane C14	0.467	1.020	0.111
Eicosane C20	0.926	0.752	25.071
Docosane C22	-	35.675	-
C25	1.764	9.135	0.804
C26	13.612	2.401	1.133
C28	0.320	2.111	0.298
C29	0.137	2.741	0.193
β -amyrine	-	7.884	-
Total (Identified)	17.226	62.247	27.61

time 85 min. Identification of the fatty acid methyl ester was carried out by GLC through direct comparison of retention times of each of the separated compounds with those of certain available authentic samples of the fatty acid methyl esters analyzed under the same conditions. Quantitation was based on peak area integration. GLC conditions were stationary phase: 10% diethylene glycosuccinate (DEGS) packed column, oven temperature 170°C, detector temperature 300°C, injector temperature 250°C, carrier gas N₂, flow-rate 30 ml/min, air flow-rate 350 ml/min; H₂ flow-rate 350 ml/min, detector FID, chart speed 2 cm/min.

Design of the clinical study

Patients with active rheumatoid arthritis were divided into four groups, each group comprised of twenty-eight patients. Three groups (after stopping medication with synthetic drugs) were given daily oral dose of 2 g of either fish oil, evening primrose oil or *Nigella sativa* oil separately in forms of capsules (in two divided doses), in addition, they were given 100 mg vitamin E/day orally as an antioxidant. The fourth group of patients was given synthetic anti-inflammatory drugs (combination of steroidal, non-steroidal and immunosuppressive) used in the treatment of rheumatoid arthritis, this group served as reference group. The experiment continued for two months.

Biochemical analysis of blood of rheumatoid arthritis patients were carried out at the start and end of the clinical study. Duration of morning stiffness and time of walking were also followed.

Biochemical analysis of blood

Blood samples were obtained from subjects after an overnight fast. Each blood sample was divided into three parts one mixed with trisodium citrate for determination of

erythrocyte sedimentation rate (12), the second part mixed with heparin for separation of plasma and determination of copper (13), zinc (14), vitamin C (15), vitamin E (16), aspartate transaminase (17), alanine transaminase (17), uric acid (18), creatinine (19), and prostaglandin E₂ (20), and the third part without addition of anticoagulant for separation of sera for the determination of C-reactive protein (21) and rheumatoid factor (22). Plasma and serum were kept at -20°C until analyzed. For erythrocyte superoxide dismutase determination (23), 0.9% NaCl was added to the red cell layer of the centrifugate, the red cells were centrifuged and washed three times and stored in a plastic tube at -20°C until analyzed.

The biochemical parameters of patients were compared before and after natural oils or synthetic drug supplementation using statistical analysis of Student's t-test (2-tailed).

Biochemical parameters after natural oils or synthetic drug supplementation were analyzed by one-way ANOVA when significant difference were found, a Tukey test was performed at a probability of p=0.05 (24).

RESULTS AND DISCUSSION

The results of investigation of unsaponifiable matter (Table 1) showed that the percentage of hydrocarbons (as percentage of total hydrocarbons) identified in unsaponifiable matter was 17.226, 62.247 and 27.61 in fish oil, primrose oil and in *Nigella sativa* oil respectively. Hexasane the main hydrocarbon identified in fish oil C26 was (13.612%), while the major hydrocarbone in primrose oil is Docosane (C22) (35.675%), but the main hydrocarbon in *Nigella sativa* oil is eicosane (C20) (25.071%). β -amyrine, a triterpenoidal matter, is identified only in primrose oil (7.884%). GLC analysis of the

fatty acids (Table 2) showed the presence of palmitic, oleic and linoleic acids in the three oils under investigation, while myristic and linolenic acids were only present in *Nigella sativa* oil and fish oil. δ -linolenic acid was present only in primrose oil. Linoleic acid may be considered as the major fatty acid present in primrose oil and *Nigella sativa* oil, while eicosapentaenoic acid was the major fatty acid present in fish oil.

Concerning primrose oil, the percentage of saturated fatty acids was 10.843%, palmitic acid was the major one (9.367%), while the percentage of unsaturated fatty acid was 87.978%, linoleic acid was the major one (62.941%). This oil contains δ -linolenic acid as 12.607%.

In the present study the percentage of saturated fatty acids in *Nigella sativa* oil was 9.658% and they were represented only by palmitic acid, while the unsaturated fatty acids represent 85.141%, and linoleic acid was the major one (46.036%). The percentage of ω -3 fatty acid was 18.188% as linolenic acid.

In the current study the percentage of identified saturated fatty acids of fish oil was (14.403%) and palmitic acid was the major one (9.602%), while the percentage of identified unsaturated fatty acids was (36.155%), and eicosapentaenoic acid was the major one (11.534%). The percentage of identified ω -3 fatty acids were 23.353% in fish oil which were represented by linolenic,

eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic (3.212, 11.534, 3.143 and 5.464% respectively).

Biochemical changes in rheumatoid arthritis patients after 2-month-treatment with synthetic drugs or natural oils

In a previous study (25) when the biochemical parameters of rheumatoid arthritis patients were compared with control healthy subjects, there was significant increase of ESR, serum CRP, RF, plasma PGE₂, Cu, activity of AST, ALT, creatinine, uric acid and activity of erythrocyte SOD with significant reduction of plasma zinc, vitamin C and vitamin E. The biochemical parameters of rheumatoid arthritis patients before and after 2 months supplementation of the natural oils or synthetic drugs are present in Table 3. There was a significant reduction in erythrocyte sedimentation rate in fish oil, primrose oil, and *Nigella sativa* oil groups ($p < 0.001$, < 0.005 and < 0.05 respectively), while a non-significant reduction was shown in synthetic drugs group. It was reported that erythrocyte sedimentation rate is the best parameter (better than C-reactive protein and rheumatoid factor) to be followed for evaluating the efficacy of new anti-inflammatory agents in rheumatoid arthritis (26). This means that natural oils used in our study might have a therapeutic effect towards rheumatoid arthritis.

Table 2: Fatty acids of the different natural fixed oils (as % of total fatty acids).

Fatty acids	Fish oil	Primrose oil	<i>Nigella sativa</i> oil
Myristic acid (C14:0)	3.682	-	Traces
Palmitic acid (C16:0)	9.602	9.367	9.658
Stearic acid (C18:0)	1.119	1.476	-
Oleic acid (C18:1 ω -9)	2.666	12.430	20.917
Linoleic acid (C18:2 ω -9)	10.136	62.941	46.036
δ -Linolenic acid (C18:3 ω -6)	-	12.607	-
Linolenic acid (C18:3 ω -3)	3.212	-	18.188
EPA (C20:5 ω -3)	11.534	-	-
DPA (C22:5 ω -3)	3.143	-	-
DHA (C22:6 ω -3)	5.464	-	-
Total identified saturated fatty acids	14.403	10.843	9.658
Total identified unsaturated fatty acids	36.155	87.978	85.141
Total ω -6 fatty acid	10.136	75.548	46.036
Total ω -3 fatty acid	23.353	-	18.188

EPA: Eicosapentaenoic acid

DPA: Docosapentaenoic acid

DHA: Docosahexaenoic acid

Serum C-reactive protein showed a non-significant reduction in all groups. Serum rheumatoid factor was non-significantly reduced in synthetic drugs group and did not change from baseline in natural oils groups. Synthetic drugs used in the present study included immune suppressive drugs and corticosteroidal that has been reported to inhibit the immune function (27). In the present study natural oils were administered after stopping synthetic drugs, so natural oils did not produce any deterioration of these parameters (C-reactive protein, rheumatoid factor) but they keep the level as it is which reflect the beneficial effects of these oils. ω -3 and ω -6 polyunsaturated fatty acids (which are present in high percentage in the natural oils under study) can modulate immune and inflammatory cell functions by eicosanoid-mediated effects (28). Long chain fatty acids such as palmitic, stearic, docosahexaenoic acid, eicosapentaenoic acid and δ -linolenic etc. (primrose oil, fish oil and *Nigella sativa* oil are rich in long chain fatty acids) have been reported to have anti-denaturant activity, protect against protein denaturation, which might have beneficial effects in rheumatoid arthritis and other rheumatic conditions (29). These fatty acids have the capability of stabilizing endogenous protein such as serum albumin and perhaps other proteins (through binding the proteins). This stabilization could prevent changes of antigenicity due to protein denaturation and glycosylation, which may trigger pathological autoimmune responses (30) suggesting that this action may be involved in the mode of action of fish oil, *Nigella sativa* oil and primrose oil in rheumatoid arthritis and other chronic inflammatory diseases. It has been reported that fish oil anti-denaturant activity was higher than non-steroidal anti-inflammatory drugs like phenylbutazone and indomethacin (29).

Plasma level of prostaglandin E₂ was significantly reduced in all patients groups; fish oil group ($p < 0.001$), primrose oil, *Nigella sativa* oil ($p < 0.05$) and synthetic drugs ($p < 0.005$), which means that the natural oils were comparable with synthetic drugs in inhibiting the inflammatory mediator prostaglandin E₂.

Arachidonic acid, the mother substance of the pro-inflammatory eicosanoid, is released from membrane phospholipids through phospholipase A₂ in the course of inflammatory activation and is metabolized by cyclooxygenase and lipoxygenase to prostaglandins and leukotrienes respectively.

Synthetic drugs such as steroidal anti-inflammatory drugs inhibit prostaglandin E₂ by stimulating lipocortin (proteins) which inhibit phospholipase A₂ activity preventing the release of arachidonic acid (31). However, non-steroidal anti-inflammatory drugs block prostaglandin and thromboxane formation by inhibiting cyclooxygenase activity. Indomethacin, in addition inhibits phospholipase by increasing intracellular cyclic adenosine monophosphate (31). Steroidal anti-inflammatory drugs are able to inhibit both cellular and fluid egress from the vascular space to inflammatory sites and inhibit the function of cell involved in the inflammation process (27).

Dietary supplementation of long chains ω -3 fatty acids like eicosapentaenoic acid and docosahexaenoic acid competitively inhibits the oxygenation of arachidonic acid by cyclooxygenase. In addition eicosapentaenoic acid is able to act as a substrate for both cyclooxygenase and 5-lipoxygenase leading to inhibition of the inflammatory mediator prostaglandin E₂ and leukotriene B₄. Ingestion of fish oils decrease membrane arachidonic acid and concomitantly decrease the capacity to synthesize eicosanoids from arachidonic; eicosapentaenoic acid gives rise to the 3-series prostaglandins and thromboxans and the 5-series leukotrienes (28,32,33).

Evening primrose oil contain large amount of δ -linolenic acid (18:3, ω -6) which can be converted by an elongase enzyme to dihommo- δ -linolenic acid (20:3, ω -6). Dihommo- δ -linolenic acid competes with arachidonate for oxidative enzymes, thereby reducing production of cyclooxygenase products derived from arachidonate. Dihommo- δ -linolenic acid is oxidized by cyclooxygenase to prostaglandin E₁, a monoenoic prostaglandins that has altered biologic activities from the dienoic prostaglandin E₂. Prostaglandin E₁ has known anti-inflammatory and immunoregulating properties (34-36). Dihommo- δ -linolenic acid itself cannot be converted to leukotrienes but can from a 15-hydroxyl derivative that blocks the transformation of arachidonic acid to leukotrienes. So dihommo- δ -linolenic acid acts as a competitive inhibitor of 2-series prostaglandins and 4-series leukotrienes and thus suppresses inflammation (3,37-42).

It has been reported that the crude fixed oil of *Nigella sativa* seed which is rich in thymoquinone and

Table 3: Different biochemical parameters of RA patients before and after 2- month treatment with synthetic drugs or different natural oils.

Parameters	Synthetic drugs		Fish oil		Primrose oil		<i>Nigella sativa</i> oil		Control healthy
	Before	After	Before	After	Before	After	Before	After	
	Means±SD		Means ±SD		Means±SD		Means±SD		
ESR (mm/h)	63.3±4.7	52.7±4.6	52.7±3.7	34.3±3.7****	58.7±3.7	42.7±2.8****	52.8±5.6	37.7±4.7*	9.8±0.431
Change (%)		-21		-35		-27		-29	
Serum									
CRP (mg/l)	50.1±5.6	46.5±6.1	43.5±5.9	40.7±6.1	45±5.7	40.7±5.5	46.3±5.6	44.1±5.9	0
Change (%)		-7		-6		-10		-5	
RF (IU/ml)	111.4±25.5	108.6±25.7	51.4±16.821	51.4±16.821	114.3±22.2	114.3±22.2	104.3±22.6	104.3±22.6	0
Change (%)		-3		0		0		0	
Plasma									
PGE ₂ (pg/ml)	1112.5±30.9	962.5±25.5****	1097.5±21.3	937.5±24.5*****	1011.3 ±22.9	921.3±26.5*	1057.5±18.6	991.3±19.3*	184.3±10.4
Change (%)		-14		-15		-9		-6	
Cu (ug/dl)	141.1±2.8	116.7±2.6*****	130.6±2.7	106.8±2.9*****	128.6±2.9	116.7±2.6****	133.4±2.8	119.8±2.4*****	97.2±2.837
Change (%)		-17		-19		-9		-10	
Zn (ug/dl)	51.3±1.7	55.1±1.7	58.3±2.2	75.2±2.2*****	64.9±1.5	73.2±1.2*****	61.1±2.6	68.9±2.4*	87.03±1.83
Change (%)		7		29		13		13	
Vit. E (mg/100 ml)	0.557±0.02	0.582±0.01	0.549±0.091	0.596±0.016	0.526±0.013	0.597±0.01*****	0.565±0.02	0.623±0.03	0.663±0.013
Change (%)		5		9		13		10	
Vit. C (mg/100 ml)	0.623±0.019	0.678±0.015*	0.614±0.02	0.721±0.02*****	0.539±0.018	0.612±0.019***	0.676±0.029	0.77±0.023	0.819±0.025
Change (%)		9		17		14		14	
Uric acid (mg/100 ml)	5.9±0.292	5.1±0.226*	5.9±0.275	5.2±0.195**	6.3±0.275	5±0.203*****	5.8±0.372	5.3±0.23	4.1±0.166
Change (%)		-16		12		-21		-9	
Creatinine (mg/100 ml)	0.914±0.032	0.941±0.032	1.02±0.026	0.892±0.03****	1.05±0.033	0.883±0.02*****	1.01±0.038	0.874±0.21****	0.872±0.038
Change (%)		-3		13		-16		-14	
AST (IU/ml)	25.1±1.68	25.5±1.69	23.8±1.45	19.1±1.03**	25.9±1.20	23.3±1.09	26.3±1.53	22.6±1.41	16.6±0.913
Change (%)		-2		-20		-10		-14	
ALT (IU/ml)	28.9±1.59	29±1.50	29.8±1.18	24.8±1.003****	28.6±1.25	25.8±0.99	28.8±1.48	24.9±1.58	18.9±0.865
Change (%)		-1		-17		-10		-14	
Erythrocyte									
SOD (U/g Hb)	2710.9±68.8	2532.1±62.8	2779.9±89.3	2502.8±81.3*	2657.8±72.9	2431.2±56.8**	2681.4±54.1	2461.1±61.2****	2256±39.65
Change (%)		-7		-10		-9		-8	

Values statistically significant when after compared with before:

*p<0.05, **p<0.025, ***p<0.01, ****p<0.005, *****p<0.001

ω -3 fatty acids inhibited the cyclooxygenase and 5-lipoxygenase pathways of arachidonate metabolism resulting in eicosanoid inhibition (8). β -sitosterol which has been reported to present in *Nigella sativa* oil (43) has been shown previously to possess anti-inflammatory activity (44). ANOVA and Tukey tests (Table 4) showed non-significant difference between the effects of the different modes of treatment on erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor and prostaglandin E₂ i.e. no treatment was superior on the other.

Concerning the antioxidant state, erythrocyte superoxide dismutase activities was reduced significantly in *Nigella sativa* oil, primrose oil and fish oil groups ($p < 0.01$, < 0.025 , < 0.05 respectively), while a non-significant reduction was noticed in synthetic drugs group. Reduction of erythrocyte superoxide dismutase activities may result in decreased reactive oxygen species generation although erythrocyte superoxide dismutase is considered as antioxidant (45). When the increased superoxide dismutase activity in rheumatoid arthritis patients was not compensated by increase in glu-

tathione peroxidase or catalase (46) there would be increased due to accumulation of superoxide ion. So the superoxide dismutase reducing effect of the natural oil in the present study has a beneficial effect in reducing the oxidation stress of patients. Plasma copper showed significant reduction in all patients' groups after treatment with fish oil, *Nigella sativa* oil, synthetic drugs groups ($p < 0.001$) and primrose oil group ($p < 0.005$). There were significant increases in plasma zinc in fish oil, primrose oil and *Nigella sativa* oil groups ($p < 0.001$, < 0.001 , < 0.05 respectively), while that of synthetic drugs group increased non-significantly. Copper and zinc are not antioxidant until they are incorporated into the antioxidant enzyme (superoxide dismutase). Plasma vitamin E was increased non-significantly in fish oil, *Nigella sativa* oil and synthetic drugs groups, while significantly increased in primrose oil group ($p < 0.001$). Significant increases in plasma vitamin C were observed in fish oil, primrose oil and synthetic drugs groups ($p < 0.001$, < 0.01 , < 0.05 respectively). *Nigella sativa* group showed a non-significant increase in plasma vitamin C. Plasma uric acid was reduced sig-

Table 4: Changes of different biochemical parameters (mean \pm SE) (These values were obtained when data before treatment were subtracted from those after treatment) of rheumatoid arthritis patients after administration of the different natural oils or synthetic drugs.

Parameters	Synthetic drugs	Fish oil	Primrose oil	<i>Nigella sativa</i> oil	ANOVA p values
ESR (mm/h)	-13 \pm 1.809	-17.4 \pm 1.809	-16 \pm 1.661	-15 \pm 1.551	NS
Serum					
CRP (mg/l)	-3.6 \pm 1.357	-3.6 \pm 1.616	-4.3 \pm 2.045	-2.1 \pm 1.078	NS
RF (IU/ml)	-2.86 \pm 1.982	0	0	0	NS
Plasma					
PGE ₂ (pg/ml)	-150 \pm 17.42	-160 \pm 15	-90 \pm 10.856	-66.3 \pm 6.798	NS
Cu (μ g/dl)	-8.79 \pm 0.649	-23.9 \pm 2.33	-11.9 \pm 1.179	-13.6 \pm 1.266	0.000068**
Zn (μ g/dl)	3.83 \pm 0.647	16.9 \pm 1.76	8.32 \pm 1.406	7.8 \pm 0.736	0.000006**
Vit. E (mg/dl)	0.025 \pm 0.007	0.078 \pm 0.016	0.074 \pm 0.024	0.059 \pm 0.018	0.049
Vit. C (mg/dl)	0.055 \pm 0.012	0.109 \pm 0.015	0.071 \pm 0.011	0.074 \pm 0.019	NS
Uric acid (mg/100ml)	-0.823 \pm 0.119	-0.75 \pm 0.121	-1.36 \pm 0.182	-0.445 \pm 0.337	NS
Creatinine (mg/100ml)	0.27 \pm 0.022	-0.132 \pm 0.024	-0.164 \pm 0.025	-0.141 \pm 0.031	0.00003**
AST (U/l)	0.357 \pm 0.799	-5 \pm 0.901	-2.61 \pm 0.464	-3.61 \pm 0.698	0.003*
ALT (U/l)	0.143 \pm 0.822	-4.96 \pm 0.948	-2.79 \pm 0.770	-3.86 \pm 0.473	0.001*
Erythrocyte					
SOD (U/gHb)	-178.6 \pm 17.57	-281.9 \pm 38.23	-226.6 \pm 26.86	-220.3 \pm 18.54	NS

Values statistically significant: * $p < 0.05$, ** $p < 0.01$, NS: Non-significant

nificantly in fish oil, primrose oil and synthetic drugs groups ($p < 0.025$, < 0.001 , < 0.05 respectively). Non-significant reductions were noticed in *Nigella sativa* oil group. Uric acid has an antioxidant activity in normal level (47), however nothing was reported about this activity when elevated over normal so the reduction towards normal level may have a beneficial effect as antioxidant. When applying the ANOVA and Tukey test on the plasma antioxidant levels, no significant differences were shown between the different treatments.

In the present study 100 mg vitamin E was given to each patient as daily oral dose concomitantly with the natural oils to optimize the beneficial anti-inflammatory effect of polyunsaturated fatty acids and minimize lipid peroxidation and free radical generation. It was reported that ingestion of ω -3 polyunsaturated fatty acids without adequate antioxidant protection could result in increased free radical formation and lipid peroxidation (48, 49), and decreased antioxidant (especially vitamin E) leading to reduction in T cell-mediated function, natural killer cell activity, and macrophage cytotoxicity. These risks associated with the intake of ω -3 polyunsaturated fatty acids may be minimized without compromising its beneficial effects by the intake of appropriate levels of antioxidants such as vitamin E. Moreover, some authors suggested that the beneficial effects of fish oil could be enhanced by the addition of 500 IU of vitamin E in the diet (50).

The study of DeLa-Cruz *et al.* (51) showed that dietary supplementation with evening primrose oil decreased tissue oxidative stress, through reduction of lipid peroxidation where glutathione was increased in all tissues and percentage of oxidized glutathione decreased since the oil increased the activities of glutathione reductase.

The inhibition of oxidative stress by the oil of *Nigella sativa* is expected from its content of thymoquinone and polyphenol and extra tocopherol that were reported to be associated with *Nigella sativa* oil (43).

Improving the state of rheumatoid arthritis due to anti-eicosanoid activity and protein anti-denaturant effect of natural oils may lead to consequent reduction of reactive oxygen species generation and simultaneous increase of antioxidant state. In addition administration of vitamin E concomitantly with the natural oil elevate plasma vitamin E level and consequently vita-

min C level that will not be consumed in regeneration of vitamin E involved in breaking the free radical chain. Moreover during improvement of the disease, vitamin C involved in collagen resynthesis will diminish leading to increasing its plasma level.

Trace elements (copper and zinc) showed restoration towards normal level after natural oils supplementation due to improved disease state since the cause affecting their changes (as reported previously) (25) were diminished. ANOVA and Tukey test showed fish oil to be superior in reducing plasma copper and elevating plasma zinc ($p = 0.000068$ and 0.000006 respectively).

A significant decrease in plasma creatinine was noticed in fish oil, primrose oil and *Nigella sativa* oil groups ($p < 0.005$, < 0.001 , < 0.005 respectively), while synthetic drugs group showed a non-significant increase in plasma creatinine. ANOVA and Tukey test showed primrose oil to have superiority in reducing creatinine plasma level compared with other natural oils ($p = 0.00003$). Plasma activities of aspartate transaminase and alanine transaminase decreased significantly in fish oil group ($p < 0.025$, < 0.005 respectively). Non-significant decreases were noticed in primrose oil and *Nigella sativa* oil groups. Synthetic drugs group showed a non-significant increase in plasma aspartate transaminase and alanine transaminase. The study of El-Dakhkhny *et al.* (52) showed that daily administration of *Nigella sativa* oil did not adversely affect the serum transaminase (ALT and AST), alkaline phosphatase, serum bilirubin or prothrombin activity. In the present study ANOVA and Tukey test showed that fish oil was the best in reducing plasma aspartate transaminase and alanine transaminase activities compared with the other natural oils (p , 0.003 and 0.001, respectively).

These results are of beneficial effect since in a previous study (25) we have noticed that the rheumatoid arthritis patients (baseline) have elevated serum level of creatinine, aspartate transaminase, alanine transaminase which might be due to either the disease itself or the synthetic drug used in the treatment. It was reported that methyl prednisolone therapy in rheumatoid arthritis produced elevation in alanine amino transferase (53). Previous studies have shown significant elevation of serum activities of transaminases and creatinine level associated with methotrexate therapy in patients with chronic inflammatory diseases (54-56).

It is worthy to mention that in the present study the duration of morning stiffness of joints has been diminished after natural oils' administration, which was 19.5 ± 1.529 min at the start of study and became 14.5 ± 1.295 min after natural oil administration. Morning stiffness occurred due to synovial congestion, effusions and thickening of joint capsules, its duration is considered an index of activity of the disease (57).

Rheumatoid arthritis patients (when foot is affected) suffered difficulty in walking and standing. The maximum time of walking in the present study was noticed to be 36.6 ± 1.386 min at the start and became 46.8 ± 0.899 after oils' treatment. Dietary supplementation with fish oil was shown previously to improve clinical parameters of disease activity including the number of tender joint and morning stiffness (58-61). It has been also reported that supplementation of human diet with dihomo- δ -linolenic acid attenuates clinical symptoms of chronic inflammatory disorders including rheumatoid arthritis (62).

In the current study gastrointestinal tract disturbances of rheumatoid arthritis patients (as side effects of synthetic drugs), have been improved after stopping the synthetic drugs and starting the administration of natural oils.

CONCLUSION

Fish oil, primrose oil and *Nigella sativa* oil have anti-inflammatory activity and can be used with successful results in rheumatoid arthritis patients. Vitamin E (as antioxidant) might essentially have provided in adjunct with the natural oils to optimize the beneficial anti-inflammatory effects of the polyunsaturated fatty acids. Liver and kidney functions were improved during natural oil treatments.

On recommendation, fish oil, primrose oil and *Nigella sativa* oil (with vitamin E) are recommended to be given in rheumatoid arthritis patients. These natural oils might be given alone or during treatment with synthetic drugs to permit reduction of dose level of the later, so as to minimize their side effects. We recommend prospective studies on the use of these natural oils either alone or in conjunction of different anti-inflammatory synthetic drugs (which may have synergistic effects with each other) for longer periods of time in rheumatoid arthritis patients.

REFERENCES

1. Dybwad A, FØrre Ø, Sioud M : Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis. *Ann Rheum Dis*, 55:437-441, 1996.
2. Belch JF : Eicosanoids and rheumatology: inflammatory and vascular aspects. *Prostaglandina Leukot Essent Fatty Acids*, 36:219-234, 1989.
3. Belch JF, Hill A : Evening primrose oil and borage oil in rheumatologic conditions. *Am J Clin Nutr*, 71:352S-356S, 2000.
4. Fortin PR, Lew RA, Liang MH : Validation of a meta-analysis: the effects of fish oil in rheumatoid arthritis. *J Clin Epidemiol*, 48: 379-390, 1995.
5. Deluca P, Rothman D, Zurier RB : Marine and botanical lipids as immunomodulatory and therapeutic agents in the treatment of rheumatoid arthritis. *Rheum Dis Clin North Am*, 21:759-777, 1995.
6. Manku MS, Morse N, Belch JF : Effects of gamma-linolenic acid supplementation on plasma essential fatty acids. *Prog Lipid Res*, 25:469-473, 1986.
7. Al-Okbi S, Ammar MN, Abd El-Kader MM : Studies of some biochemical, nutritional and anti-inflammatory effects of *Nigella sativa* seeds. *Egypt J Pharm Sci*, 38:451-469, 1997.
8. Houghton PJ, Zarka R, de las Heras B, Hoult JR : Fixed oil of *Nigella sativa* and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. *Planta Med*, 61:33-36, 1995.
9. Chakravarty N : Inhibition of histamin release from mast cells by nigellone. *Annals of Allergy*, 70:237-242, 1993.
10. E-Said ME, Amer MM : Oils, Fats, Waxes and Surfactants; *Anglo-Egyptian Bookshop, Cairo*, pp 130-132, 1965.
11. *British Pharmacopeia*, 1, The Pharmaceutical Press, London.
12. Westergren A : Studies of the suspension stability of the blood in pulmonary tuberculosis. *Acta Medica Scandinavica*, 54:247, 1921.
13. Zak B : Simple procedure for the single sample determination of serum copper and iron. *Clin Chim Acta*, 3:328, 1958.
14. Makino T, Saito M, Horiguchi D, Kina K : A highly sensitive colorimetric determination of serum zinc using water-soluble pyridylazo dye. *Clinica Chimica Acta*, 120:127-135, 1982.
15. Jagota SK, Dani HM : A new colorimetric technique for the estimation of vitamin C using folin phenol reagent, 1982.
16. Desia ID, Machlin LJ : Vitamin E : In methods of vitamin assay. Ed by J Augustin, BP Klein, D Becker, PB Venugopal, 4th edition. A widely Interscience Publication John Wiley and Sons, New York, pp 255-275, 1985.

17. Reitman S, Frankel S : Calorimetric methods for aspartate and alanine aminotransferase. *Am J Clin Path*, 28:55, 1957.
18. Watts RWE : Determination of uric acid in blood and urine. *Ann Clin Biochem*, 11, 103-111, 1974.
19. Houot O : Interpretation of clinical laboratory tests. Edit Siest g, ed by J Henny, F Schiele, DS Young. Biomedical Publications, 1985.
20. Hayaishi O : Sleep-wake regulation by prostaglandin D₂ and E₂. *J Biol Chem*, 263:14593-14596, 1988.
21. Ziegenhagen G, Drahovsky D : Klinische Bedeutung des C-reaktiven protein. *Med Klin*, 78:24-35, 1983.
22. Muller W : The serology of rheumatoid arthritis. Berlin Goettingen-Heidelberg, p 97, 1962.
23. Roth EF, Gilgert HS : The pyrogallol assay for superoxide dismutase: absence of glutathione artifact. *Anal Biochem*, 137:50, 1984.
24. SPSS : Statistical package for the social sciences. SPSS Inc., 1996.
25. Al-Okbi SY, Soroor Kh, Abdel Samed AM, Rashed MM, Mohamed AD : Nutritional status and blood antioxidant levels of Egyptian rheumatoid arthritis patients. *Kaser El-Aini Medical Journal*, 6:43-64, 2000.
26. Arvidsson NG, Gudjonsson B, Hallgren R, Larsson A : Concordant message of different inflammatory markers in patients with rheumatoid arthritis. *Upsala J Med Sci*, 103:35-42, 1998.
27. Spiegel TM : Practical rheumatology, printed by A Wiley, Medical Publication. Jhon Wiley and Sons, USA pp 169-172, 1983.
28. Calder PC : Dietary fatty acids and the immune system. *Nutr Rev*, 56:S70-S83, 1998.
29. Saso L, Valentini G, Casini ML, Mattei E, Braghiroli L, Mazzanti G, Panzironi C, Grippa E, Silvestrini B : Inhibition of protein denaturation by fatty acids, bile salts and other natural substances: a new hypothesis for the mechanism of action of fish oil in rheumatic diseases. *Jpn J Pharmacol*, 79:89-99, 1999.
30. Saso L, Valentini G, Mattei E, Panzironi C, Casini ML, Grippa E, Silvestrini B : Stabilization of rat serum proteins following oral administration of fish oil. *Arch Pharm Res*, 22:485-490, 1999.
31. Katzung GB : Basic clinical pharmacology. 5th edition, Appleton and Lange, Apulishing Division of Prentice Hall, pp 263-277, 1992.
32. Heller A, Koch T, Schmeck J, van Ackern K : Lipids mediators in inflammatory disorders. *Drugs*, 55:487-496, 1998.
33. James MJ, Gibson RA, Cleland LG : Dietary polyunsaturated fatty acids and inflammatory mediator production. *Am J Clin Nutr*, 71:343S-348S, 2000.
34. Ziboh VA, Chapikin RS : Biologic significance of polyunsaturated fatty acids in the skin. *Arch Dermatol*, 123:1686-1690, 1987.
35. Zurier RB : Prostaglandin E₁: Is it useful? *J Rheumatol*, 17:1439-1441, 1990.
36. Kelley WN, Harris ED, Ruddy S, Sledge CB : Textbook of rheumatology 4th edition, Philadelphia: WB Saunders company. Philadelphia, pp 484-497, 853-854, 1993.
37. Vanderhoek JY, Bryant RW, Bailey JM : Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. *J Biol Chem*, 255:10064-10066, 1980.
38. Billah MM, Bryant RR, Siegel MI : Lipoxygenase products of arachidonic acid modulate the biosynthesis of platelet-activating factor (1-o-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by human neutrophils via phospholipase A₂. *J Biol Chem*, 260:6899-6906, 1985.
39. Iversen L, Fogh K, Bojesen G, Karagballe K : Linolenic acid and dihomogammalinolenic acid inhibit leukotriene B₄ formation and stimulate the formation of their 15-lipoxygenase products by human neutrophils in vitro. Evidence of formation of anti-inflammatory compounds. *Agents Actions*, 33:286-291, 1991.
40. Iversen L, Fogh K, Bojesen G, Karagballe K : Effect of DHGLA and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: selective inhibition of the 5-lipoxygenase pathway. *Arch Dermatol Res*, 284:222-226, 1992.
41. Chilton-Lopes T, Surette ME, Swan DD, Fonteh AN, Johnson MM, Chilton FH : Metabolism of gamma-linolenic acid in human neutrophils. *J Immunol*, 156:291-294, 1996.
42. DeLuca P, Rossetti RG, Alavian C, Karim P, Zurier RB : Effects of gamma-linolenic acid on interleukin-1 β and tumor necrosis factor- α secretion by stimulated human peripheral blood monocytes: studies in vitro and in vivo. *J Investig Med*, 47:247-250, 1999.
43. Nergiz C, Ötles S : Chemical composition of *Nigella sativa* L. seeds. *Foot Chemistry*, 48:259-261, 1993.
44. Gupta MB, Nath R, Srivastava N, Shanker K, Kishor K, Bhargava KP : Anti-inflammatory and anti-pyretic activities of β -sitosterol. *Planta Medica*, 39:157-163, 1980.
45. Scott MD, Meshnick SR, Eaton JW : Superoxide dismutase amplifies organismal sensitivity to ionizing radiation. *J Biol Chem*, 264:2498, 1989.
46. Gambhir JK, Lali P, Jain AK : Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. *Clin Biochem*, 30:351-355, 1997.
47. Situnayake RD, Thurnham DI, Kootatthep S, Chirico S, Lunec J, Davis M, Mc Conkey B : Chain breaking antioxidant status in rheumatoid arthritis: clinical and laboratory correlates. *Ann Rheum Dis*, 50:81-86, 1991.

48. Meydani SN : *Effect of n-3 polyunsaturated fatty acids on cytokine production and their biologic function. Nutr, 121:S8-S12, 1996.*
49. Wu D, Meydani SN : *n-3 polyunsaturated fatty acids and immune function. Proc Nutr Soc, 57:503-509, 1998.*
50. Venkatraman JT, Chu WC : *Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr, 18:602-613, 1999.*
51. DeLa-Cruz JP, Quintero L, Galvez J, Villalobos MA, Sanchez de la Cuesta F : *Antioxidant potential of evening primrose oil administration in hyperlipemic rabbits. Life Sci, 65:543-555, 1999.*
52. El-Dakhkhny M, Mady NI, Halim MA : *Nigella sativa L. oil protects against induced hepato toxicity and improves serum lipid profile in rats. Arzneimittelforschung, 50:832-836, 2000.*
53. Amosova KM, Iaremenko OB, Potapkov OV, Ivashchenko NA : *A comparative evaluation of the efficacy of peroral and intravenous pulse therapy with methylprednisolone in rheumatic diseases. Lik-Sprava, 7:48-52, 1988.*
54. Montilla-Morales C, Lopez-Longo FJ, Koreno-Zazo M, Monteagudo-Saez I, Moreno-Garcia AC, Carreno-Perez L : *Hypertransaminemia y metotrexato: es siempre un efecto toxico? Rev Clin Esp, 198:822-824, 1998.*
55. Van-den-Borne BE, Landewe RB, Goei-The HS, Breedveld FC, Dijkmans BA : *Cyclosporin a therapy in rheumatoid arthritis: only atrict application of the guidelines for safe use can prevent irreversible renal function loss. Rheumatology-Oxford, 38:254-259, 1999.*
56. Park GT, Jeon DW, Roh KH, Mun HS, Lee CH, Park CH, Kang KW, Kim SM, Kang JM, Pak HC : *A case of pancytopenia secondary to low-dose pulse methotrexate therapy in a patient with rheumatoid arthritis and renal insufficiency. Korean J Intern Med, 14:85-87, 1999.*
57. Golding DN : *Rheumatoid arthritis: Clinical features, complications, diagnosis and prognosis. In: A synopsis of rheumatic diseases, 5th edition, Page bros, Ltd, Norwich, England, p 29, 59, 1989.*
58. Kremer JM, Lawrence DA, Petrillo GF, Litts LL, Mullaly PM, Rynes RI, Stocker RP, Parhami N, Greenstein NS, Fuchs BR : *Effects of high-dose fish oil on rheumatoid arthritis after stopping non-steroidal anti-inflammatory drugs. Clinical and immune correlates. Arthritis Rheum, 38:1107-1114, 1995.*
59. Kremer JM : *Effects of modulation of inflammatory and immune parameters in patients with rheumatic and inflammatory disease receiving dietary supplementation of n-3 and n-6 fatty acids. Lipids 31:S243-247, 1996.*
60. Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH : *Omega-3 fatty acids in rheumatoid arthritis: an overview. Semin Arthritis Rheum, 27:366-370, 1998.*
61. Kremer JM : *n-3 fatty acid supplements in rheumatoid arthritis. Am J Clin Nutr, 71:349S-51S, 2000.*
62. Barham BJ, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH : *Addition of eicosapentaenoic acid to γ -linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr, 130:1925-1931, 2000.*

Correspondence:

Sahar Y. Al-Okbi

Department of

Food Sciences and Nutrition,

National Research Centre,

Dokki, Cairo,

EGYPT.

e-mail:S_Y_alokbi@hotmail.com